Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 13

1.

Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Breban R, Bisiaux A, Biot C, Rentsch C, Bousso P, Albert ML.

Oncoimmunology. 2012 Jan 1;1(1):9-17.

2.

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.

Gandhi NM, Morales A, Lamm DL.

BJU Int. 2013 Aug;112(3):288-97. doi: 10.1111/j.1464-410X.2012.11754.x. Epub 2013 Mar 20. Review.

3.

Diagnosis and management of superficial bladder cancer.

Amling CL.

Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. Review.

PMID:
11514784
4.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

5.

Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.

Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W, Brausi M.

Eur Urol. 2000;37 Suppl 3:1-9. Review.

PMID:
10828681
6.

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

Brandau S, Suttmann H.

Biomed Pharmacother. 2007 Jul;61(6):299-305. Epub 2007 Jun 12. Review.

PMID:
17604943
7.

Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.

Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK.

Urol Res. 1998;26(3):155-9. Review.

PMID:
9694595
8.

BCG and the treatment of superficial bladder cancer.

Moss JT, Kadmon D.

DICP. 1991 Dec;25(12):1355-67. Review.

PMID:
1815434
9.

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.

Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H.

Cancer Sci. 2013 Jan;104(1):22-7. doi: 10.1111/cas.12075. Epub 2013 Jan 3. Review.

10.

BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Ahirwar DK, Manchanda PK, Mittal RD, Bid HK.

J Cancer Res Clin Oncol. 2011 Dec;137(12):1729-38. doi: 10.1007/s00432-011-1056-3. Epub 2011 Sep 20. Review.

PMID:
21932129
11.

Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.

Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, Chopin DK.

Eur Urol. 2003 Apr;43(4):351-60; discussion 360-1. Review.

PMID:
12667715
12.

[The bacillus Calmette-Guérin as immunomodulator in bladder cancer].

Vázquez-Lavista LG, Flores-Balcázar CH, Llorente L.

Rev Invest Clin. 2007 Mar-Apr;59(2):146-52. Review. Spanish.

PMID:
17633803
13.

Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review.

Zuiverloon TC, Nieuweboer AJ, Vékony H, Kirkels WJ, Bangma CH, Zwarthoff EC.

Eur Urol. 2012 Jan;61(1):128-45. doi: 10.1016/j.eururo.2011.09.026. Epub 2011 Oct 6. Review.

PMID:
22000498
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk